Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zurit Levine

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Genome Research|May 9, 2002
Large-scale protein annotation through gene ontologyHanqing Xie, Alon Wasserman, Zurit Levine, et al.
American Journal of Obstetrics and Gynecology|August 4, 2009
Systematic antigenic profiling of hematopoietic antigens on ovarian carcinoma cells identifies membrane proteins for targeted therapy developmentLimor Helpman, Ben-Zion Katz, Tamar Safra, et al.
Annals of the New York Academy of Sciences|May 7, 2009
Activation of relaxin-related receptors by short, linear peptides derived from a collagen-containing precursorRonen Shemesh, Chen Hermesh, Amir Toporik, et al.
The Journal of Biological Chemistry|October 16, 2008
Discovery and validation of novel peptide agonists for G-protein-coupled receptorsRonen Shemesh, Amir Toporik, Zurit Levine, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2009
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicityNoa Stanietsky, Hrvoje Simic, Jurica Arapovic, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2009
Peptides modulating conformational changes in secreted chaperones: from in silico design to preclinical proof of conceptYossef Kliger, Ofer Levy, Anat Oren, et al.
Cancer Immunology Research|April 22, 2020
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)Julia Huetter, Uwe Gritzan, Ilona Gutcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathwayZohar Tiran, Anat Oren, Chen Hermesh, et al.
Cancer Immunology Research|May 16, 2024
PVRIG is Expressed on Stem-Like T Cells in Dendritic Cell-Rich Niches in Tumors and Its Blockade May Induce Immune Infiltration in Non-Inflamed TumorsZoya Alteber, Gady Cojocaru, Roy Z Granit, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 13, 2018
ILDR2 Is a Novel B7-like Protein That Negatively Regulates T Cell ResponsesIris Hecht, Amir Toporik, Joseph R Podojil, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Genome Research|May 9, 2002
Large-scale protein annotation through gene ontologyHanqing Xie, Alon Wasserman, Zurit Levine, et al.
American Journal of Obstetrics and Gynecology|August 4, 2009
Systematic antigenic profiling of hematopoietic antigens on ovarian carcinoma cells identifies membrane proteins for targeted therapy developmentLimor Helpman, Ben-Zion Katz, Tamar Safra, et al.
Annals of the New York Academy of Sciences|May 7, 2009
Activation of relaxin-related receptors by short, linear peptides derived from a collagen-containing precursorRonen Shemesh, Chen Hermesh, Amir Toporik, et al.
The Journal of Biological Chemistry|October 16, 2008
Discovery and validation of novel peptide agonists for G-protein-coupled receptorsRonen Shemesh, Amir Toporik, Zurit Levine, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2009
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicityNoa Stanietsky, Hrvoje Simic, Jurica Arapovic, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2009
Peptides modulating conformational changes in secreted chaperones: from in silico design to preclinical proof of conceptYossef Kliger, Ofer Levy, Anat Oren, et al.
Cancer Immunology Research|April 22, 2020
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)Julia Huetter, Uwe Gritzan, Ilona Gutcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathwayZohar Tiran, Anat Oren, Chen Hermesh, et al.
Cancer Immunology Research|May 16, 2024
PVRIG is Expressed on Stem-Like T Cells in Dendritic Cell-Rich Niches in Tumors and Its Blockade May Induce Immune Infiltration in Non-Inflamed TumorsZoya Alteber, Gady Cojocaru, Roy Z Granit, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 13, 2018
ILDR2 Is a Novel B7-like Protein That Negatively Regulates T Cell ResponsesIris Hecht, Amir Toporik, Joseph R Podojil, et al.
Pageof 1